Clinical trials: SARS-COV-2 Infection
COVID - 19
Nasal Poly-ICLC (Hiltonol®) in Healthy COVID-19 Vaccinated Adults
This is a randomized (4:1) Phase 1 b safety trial in adults who have completed their full COVID-19 vaccination schedule at least 30 days prior to study entry.
- Trial name
- NCT04672291
- Where
- Canada
- Volunteers
- 43 people, healthy volunteers welcome
- Sponsor
- Oncovir, Inc.
COVID-19
Study of the Efficacy and Safety of a Single Administration of Olokizumab vs. Placebo in Addition to Standard Treatment in Patients With Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection (COVID-19).
The primary objective of the study is to evaluate the efficacy of a single dose of OKZ (64 mg) vs placebo in addition to standard therapy in patients with severe SARS-CoV-2 infection (COVID-19) at Day 29.
- Trial name
- NCT04452474
- Testing
- Olokizumab 64 mg
- Sponsor
- R-Pharm
Long Covid19
Effectiveness of Testofen Compared to Placebo on Long COVID Symptoms
This is a double blind, randomised, placebo-controlled trial to evaluate orally-dosed Testofen (a specialised extract of Trigonella foenum-graecum (Fenugreek) seed) compared to placebo on post COVID-19 symptoms in otherwise…
- Trial name
- NCT05795816
- Testing
- Testofen, Microcrystalline cellulose
- Where
- Australia
- Volunteers
- 150 people
- Sponsor
- RDC Clinical Pty Ltd
COVID-19
Safety and Pharmacokinetics of FBR-002 for the Treatment of Patients Hospitalized With COVID-19 in Need of Supplemental Oxygen and at Risk of Severe Outcome
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is the coronavirus associated with COVID-19 (Coronavirus Disease 2019), invading the respiratory tract, and leading to symptoms from dysgeusia, anosmia, fever, headache…
- Trial name
- NCT05279352
- Testing
- FBR-002
- Where
- 6 sites in Greece
- Volunteers
- 30 people
- Sponsor
- Fab'entech
Influenza,Human, COVID-19
A Study to Learn About Flu and COVID-19 Vaccine Responses in Healthy People
This study is to learn about flu and COVID vaccines, either alone or when mixed together. Healthy people aged 18 or older can join. Participants will get one shot in each arm, either a flu or COVID vaccine, alone or mixed.
- Trial name
- NCT06683352
- Testing
- Investigational Influenza Vaccine, COVID-19 Vaccine, Investigational Influenza/COVID-19 Vaccine
- Where
- 22 sites in United States
- Volunteers
- 1,353 people, healthy volunteers welcome
- Sponsor
- BioNTech SE
COVID -19, COVID-19 (Prevention)
A Study Evaluating MDX2301 in Healthy Adults and Adults at Higher Risk for Severe COVID-19.
This first-in-human study is designed to evaluate the safety, tolerability, pharmacokinetics, anti-drug antibodies, and neutralizing activity of MDX2301 administered by intravenous (IV), intramuscular (IM), or subcutaneous (SC)…
- Trial name
- NCT07445971
- Testing
- MDX2301, Normal Saline
- Where
- 2 sites in United States
- Volunteers
- 80 people, healthy volunteers welcome
- Sponsor
- ModeX Therapeutics, An OPKO Health Company
Coronavirus Infection, Covid-19
Pilot Study of Ensifentrine or Placebo Delivered Via pMDI in Hospitalized Patients With COVID-19
This pilot study is being performed to assess the efficacy and safety of inhaled ensifentrine delivered via pMDI compared with a matching placebo in conjunction with standard of care treatments on recovery in patients…
- Conditions
- Coronavirus Infection, Covid-19, SARS-CoV-2
- Trial name
- NCT04527471
- Testing
- Ensifentrine Dose 1
- Where
- United States
- Volunteers
- 45 people
- Sponsor
- Verona Pharma Inc
Immunocompromised
A Study to Evaluate Efficacy and Safety of Casirivimab+Imdevimab (Monoclonal Antibodies) for Prevention of COVID-19 in Immunocompromised Adolescents and Adults
The primary objective of the study is to evaluate the effect of casirivimab+imdevimab, compared with placebo, in preventing symptomatic SARS-CoV-2 infection in immunocompromised participants.
- Trial name
- NCT05074433
- Testing
- casirivimab+imdevimab
- Where
- 67 sites in United States, Mexico
- Volunteers
- 66 people
- Sponsor
- Regeneron Pharmaceuticals
COVID-19
Study of the Use of Favipiravir in Hospitalized Subjects With COVID-19
To determine the effect of favipiravir + SOC v. SOC on COVID-19 viral clearance.
- Trial name
- NCT04358549
- Testing
- Favipiravir, Standard of Care
- Where
- 8 sites in United States
- Volunteers
- 50 people
- Sponsor
- Fujifilm Pharmaceuticals U.S.A., Inc.
Coronavirus Infection, COVID
Monovalent Recombinant COVID19 Vaccine
This is a study to test a new vaccine (Covax-19) against COVID-19. COVID-19 is a potentially deadly disease that is caused by a new strain of coronavirus called SARS-CoV-2.
- Trial name
- COVAX19 (NCT04453852)
- Testing
- COVID19 vaccine, Saline
- Where
- Australia
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Vaxine Pty Ltd
COVID-19 Pneumonia
Pharmacokinetics and Safety of GST-HG171 Tablets in Subjects With Impaired and Normal Renal Function
This si a single-center, non-randomized, open, parallel, single-dose trial was designed to evaluate the safety and pharmacokinetic characteristics of GST-HG171 tablets in subjects with impaired renal function.
- Trial name
- NCT06106126
- Testing
- GST-HG171 Tablets
- Where
- China
- Volunteers
- 32 people, healthy volunteers welcome
- Sponsor
- Fujian Akeylink Biotechnology Co., Ltd.
COVID-19
Immunogenicity And Safety of COVID-19 Vaccine , Inactivated Co -Administration With EV71 Vaccine (Vero Cell)
This study is a randomized and controlled phase Ⅳ clinical trial of the COVID-19 vaccine (Vero cell), Inactivated manufactured by Sinovac Research \& Development Co., Ltd.
- Trial name
- NCT04993365
- Testing
- Experimental Group, Control Group
- Where
- 2 sites in China
- Volunteers
- 520 people, healthy volunteers welcome
- Sponsor
- Sinovac Research and Development Co., Ltd.
COVID-19 Pneumonia
Phase I Clinical Trial of GEN2-Recombinant COVID-19 Vaccine (CHO Cells) in Healthy People Aged 18 and Above
phase I study will evaluate the safety and tolerability of GEN2-Recombinant COVID-19 Vaccine (CHO cells) in healthy people aged 18 years and older.
- Trial name
- NCT05408312
- Testing
- Experimental Vaccine 1, Experimental Vaccine 2, Experimental Vaccine 3
- Where
- China
- Volunteers
- 234 people, healthy volunteers welcome
- Sponsor
- National Vaccine and Serum Institute, China
SARS-CoV-2, COVID-19 Vaccines
Effectiveness of BNT162b2 Formulations Using State Vaccine Registry and Insurance Claims Data
The primary purpose of this study is to learn about how well different versions of the Pfizer-BioNTech COVID-19 vaccine (called BNT162b2) work at preventing death, severe COVID-19 that requires a trip to the hospital, and overall…
- Trial name
- NCT06199934
- Testing
- Vaccination
- Where
- United States
- Volunteers
- 19,853,610 people
- Sponsor
- Pfizer
COVID-19 Virus Infection
Clinical Trial to Evaluate the Efficacy, Immunogenicity and Safety of the Inactivated SARS-CoV-2 Vaccine (COVID-19)
This is a randomized, double blind, placebo parallel-controlled phase III clinical trial to evaluate the efficacy, immunogenicity and safety of the inactivated SARS-CoV-2 Vaccine (Vero cell) in Argentine healthy population aged…
- Trial name
- NCT04560881
- Testing
- Inactivated SARS-CoV-2 vaccine (Vero cell)
- Where
- 4 sites in Argentina
- Volunteers
- 3,000 people, healthy volunteers welcome
- Sponsor
- Laboratorio Elea Phoenix S.A.
Coronavirus Infection
NasoVAX in Patients With Early Coronavirus Infectious Disease 2019 (COVID-19)
The purpose of this study is to evaluate the safety and effectiveness of NasoVAX in preventing worsening of symptoms and hospitalization in patients with early COVID-19.
- Trial name
- NCT04442230
- Testing
- NasoVAX
- Where
- 7 sites in United States
- Volunteers
- 48 people
- Sponsor
- Altimmune, Inc.
SARS-CoV, SARS-CoV-2
Study of VXCO-100, a SARS-CoV Candidate Vaccine, in Adults in the Republic of South Africa
The purpose of this study is to evaluate the safety and immunogenicity of ascending dose levels of VXCO-100 in adults.
- Trial name
- NCT05938075
- Testing
- VXCO-100, COVID-19 mRNA vaccine
- Where
- 2 sites in South Africa
- Volunteers
- 130 people, healthy volunteers welcome
- Sponsor
- Vaccine Company, Inc, a wholly owned subsidiary of Eli Lilly and Company
2019 Novel Coronavirus Disease, 2019 Novel Coronavirus Infection
Evaluation of the AudibleHealth Dx AI/ML-Based Dx SaMD Using FCV-SDS in the Diagnosis of COVID-19 Illness: Clinical Validation
The AudibleHealth Dx is a diagnostic software as a medical device (Dx SaMD) consisting of an ensemble of software subroutines that interacts with a proprietary database of Signal Data Signatures (SDS), using Artificial…
- Conditions
- 2019 Novel Coronavirus Disease, 2019 Novel Coronavirus Infection, 2019-nCoV Disease, COVID-19 Pandemic
- Trial name
- NCT05364268
- Testing
- Diagnostic Test: Diagnostic Software as Medical Device
- Where
- United States
- Volunteers
- 514 people, healthy volunteers welcome
- Sponsor
- AudibleHealth AI, Inc.
Chronic Fatigue Syndrome, Long COVID
Endothelial Dysfunction in Post-infection Fatigue Syndromes
Post-infection chronic fatigue syndromes, such as myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS) and post-COVID-19 condition (Long Covid), are conditions primarily characterized by debilitating fatigue.
- Trial name
- NCT06463106
- Where
- Austria
- Volunteers
- 107 people, healthy volunteers welcome
- Sponsor
- FH Joanneum Gesellschaft mbH
COVID-19
Special Investigation of COMIRNATY in the Population With Underlying Diseases
Post-marketing study, Cohort study of COMIRNATY vaccines. To collect information on adverse events and COVID-19 observed after vaccination with COMIRNATY and to assess safety in patients with underlying disease considered to be…
- Trial name
- NCT04880447
- Testing
- BNT162b2
- Where
- Japan
- Volunteers
- 1,075 people, healthy volunteers welcome
- Sponsor
- Pfizer
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.